Asabys has announced that the Institut Català de Finances (ICF) has joined its new venture capital fund, Sabadell Asabys Health Innovation Investments II (Sabadell Asabys II), with 10 million euro...
AbolerIS Pharma, a Belgian biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A ...
Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner to reinforce the company’s healthcare investment team.
The 1st generation of companies participating in BCN Health Booster accelerator raised €51.8 million of public and private funding during 2022 (the first year of its launch), a figure that represent...
ADmit has secured a €5.4 million equity round with Clave Capital as the lead investor, with significant support from the EIC Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Acc...
La mayor parte de esta inversión proviene de un grupo de inversores con sede en Alicante, encabezados por el family office del abogado David Devesa, y también con la participación adicional de la f...
In the healthcare sector, renowned for its resilience and appeal to astute investors, a distinctive shift is underway. Investment funds have assumed a prominent role in M&A activities, fostering R&D p...
Agomab Therapeutics has announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company (FMR), with participation from new investors EQ...
Sidekick Health’s recent success in closing its Series B fundraising round in May 2022 laid the foundations for the company to accelerate innovation and drive even greater impact in the digital heal...
SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the signing of an exclusive collaboration and licensing agre...
CRB Inverbío amplía su portafolio con un tercer fondo de capital riesgo dedicado a proyectos de Salud Digital tanto españoles como europeos de tamaño de hasta 40 millones de euros, y expande con e...
Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and...